Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 Pharmaceutical Research Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017”. Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305521

Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/severe-acute-respiratory-syndrome-sars-pipeline-review-h2-2017-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) - Overview
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
3-V Biosciences Inc
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
CEL-SCI Corp
Fab'entech SA
GeneCure LLC
Gilead Sciences Inc
Nanotherapeutics Inc
Novavax Inc
Oncovir Inc
Phelix Therapeutics LLC
Protein Sciences Corp
Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
ATR-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSW-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-3252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-5734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ML-188 - Drug Profile
Product Description
Mechanism Of Action

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305521

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.